Phathom Pharmaceuticals, Inc. Long Term Debt (Total)

Long Term Debt (Total) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long Term Debt (Total) growth rates and interactive chart. Long-term debt is debt that matures in more than one year. The sum of long-term bank loans, debentures or bonds outstanding. Refers to interest-bearing debt. An indebted company pays interest on its debt, which is recorded on the income statement and reduces net income to common shareholders. Long-term debt is used in ratios lke Debt/Equity or Debt/Assets to determine the financial health of a business.


Highlights and Quick Summary

  • Long Term Debt (Total) for the quarter ending September 29, 2021 was $89.6 Million (a 131.4% increase compared to previous quarter)
  • Year-over-year quarterly Long Term Debt (Total) increased by 117.49%
  • Annual Long Term Debt (Total) for 2020 was $41.2 Million (a 75.94% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long Term Debt (Total) of Phathom Pharmaceuticals, Inc.

Most recent Long Term Debt (Total)of PHAT including historical data for past 10 years.

Interactive Chart of Long Term Debt (Total) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Long Term Debt (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $89.59 $38.72 $37.05
2020 $41.19 $42.71 $44.87 $45.91 $41.19
2019 $22.78 $22.61 $23.41

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.